Our Regular Weekly “Surfers”

HEP Dynamics LLC, Go To Market Advisors, LLC

Owner and Principle of HEP Dynamics, sponsor Surfing the NASH Tsunami, a weekly podcast in which a panel of experts discusses commercial developments and challenges in the global NASH market.

Hepatology Researcher & KOL

Dr. Stephen Harrison currently serves as the Medical Director for Pinnacle Clinical Research and the President of Summit Clinical Research.

Founder and Medical Director, Tawazun Health

Louise has over 35-years experience working in the Healthcare Industry in UK and elsewhere in the world, including Europe, Middle East and Australia.

Guest Surfers

Global Liver Institute

Andrew Scott leads Global live Institute’s (GLI) policy department by actively advancing patient-centric strategies through undertaking proactive legislative and regulatory initiatives that positively improve the lives of all impacted by liver disease.

NASH kNOWledge

Anthony’s experience with liver disease motivated him to form NASH kNOWledge, a non-profit corporation with the mission of increasing public awareness of nonalcoholic liver disease.

President and CEO, Global Liver Institute

Donna R. Cryer, JD is Founder, President and Chief Executive Officer of the Global Liver Institute (GLI), the only patient-driven liver health nonprofit operating in the US and Europe.

University of Leeds and Leeds Teaching Hospitals NHS Trust

Ian is a Senior Lecturer at the University of Leeds and Honorary Consultant Hepatologist at the Liver Unit at St James’s University Hospital in Leeds.

Liver Institute Northwest, Clinical Professor, Elson S. Floyd College of Medicine at Washington State University

Dr. Kris Kowdley, Director of Liver Institute Northwest and clinical professor, Elson S. Floyd College of Medicine at Washington State University, is an internationally recognized liver disease expert and researcher.

CEO of Sonic Incytes

A serial entrepreneur in healthtech, co-founding Sonic Incytes, developers of Velacur, the world’s first handheld 3D liver tissue assessment tool with diagnostic accuracy comparable to MRI elastography.

ModifyHealth

Hagan currently serves as Chief Commercial Officer at ModifyHealth. With over 15 years in the GI/Endoscopy space, Hagan has a history of commercializing innovative products and services that have dramatic impact on patient care. Prior to ModifyHealth, Hagan served as Senior Director of Marketing at EndoChoice and Marketing Channel Manager for the GI ASC Division at Boston Scientific.

Echosens North America

36 years of product development and commercialization of gastroenterology-specific diagnostic devices.

ChronWell, Inc.

Joe is the founder of gMed, the leading GI EHR platform (sold to Modernizing Medicine) and ChronWell, a digital health company focused on fatty liver disease.

National Research Institute

Dr. Juan Pablo Frias is Medical Director and Principal Investigator of National Research Institute in Los Angeles, CA. He has been involved in diabetes and metabolism-related research for over 25 years and has authored numerous publications in this field.

Akero Therapeutics

Kitty Yale joined Akero in October 2018 as Chief Development Officer. In her current role, she leads the clinical development of Efruxifermin (fc-FGF21 analog) in NASH

MPH, FACP, FACG, FAASLD Professor of Medicine Duke University

Manal F. Abdelmalek, MD, MPH is a tenured Professor of Medicine in the Division of Gastroenterology and Hepatology and Director of the Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Research Program at Duke University.

Northwestern University Feinberg School of Medicine

Dr. Rinella is a Professor of Medicine at Northwestern University Feinberg School of Medicine and is the Director of the Northwestern Fatty Liver Program.

Chief Innovation Officer, Perspectum, Ltd.

Matt Kelly is Perspectum’s Chief Innovation Officer, overseeing clinical studies and collaborations to support our technology and explore novel indications.

U Chicago Medicine

Michael Charlton, MBBS, is an internationally renowned specialist in liver diseases and transplant medicine. Listed among “America’s Top Doctors” and “Best Doctors in America,” Dr. Charlton has particular expertise in the diagnosis, treatment and management of nonalcoholic fatty liver disease (nonalcoholic steatohepatitis) and viral hepatitis.

Section Chief of Hepatology at Beth Israel Deaconess Medical Center and Associate Professor of Medicine at Harvard Medical Center.

Michael Curry is the Section Chief of Hepatology at Beth Israel Deaconess Medical Center and Associate Professor of Medicine at Harvard Medical Center.

Director of the Fatty Liver Program, Arizona Liver Health

Naim Alkhouri, M.D., is the VP of Academic Affairs, Chief of Transplant Hepatology, and Director of the Fatty Liver Program at Arizona Liver Health (ALH) in Phoenix, AZ.

Professor of Experimental Hepatology & Consultant Hepatologist at Newcastle University

Quentin M. Anstee was a guest panelist on Episode 6

South Texas Research Institute

Rashmee Patil, MD is the CEO, Medical Director of South Texas Research Institute in Edinburg, Texas

EVP and Global Head of Diagnostics at GENFIT

Suneil Hosmane, PhD has appeared as a guest surfer in episodes 8, 10, 13, 14

Managing Director, Senior Research Analyst & Co-Head of Biotechnology Research at ROTH Capital Partners

Yasmeen appeared in the first 3 episodes.